NCT05284253

Brief Summary

The investigators hypothesize gold is inert and thereby there is no pure-gold allergy. The primary aim of this study is to measure the prevalence of allergy to metallic pure gold microparticles and allergy to GSTS.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2024

Shorter than P25 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 21, 2021

Completed
4 months until next milestone

First Posted

Study publicly available on registry

March 17, 2022

Completed
2.2 years until next milestone

Study Start

First participant enrolled

June 1, 2024

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2024

Completed
Last Updated

January 30, 2024

Status Verified

January 1, 2024

Enrollment Period

3 months

First QC Date

November 21, 2021

Last Update Submit

January 26, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Patch test

    Test materials will be applied on the upper back of the volunteers in aluminium Finn Chambers for 48 hours. Clinical evaluation will be performed 24 hours after removal of the test substances according to standard procedures for evaluation of epicutaneous challenging according to criteria of ICDRG (International Contact Dermatitis Research Group) (Johansen 2015). Reactions: doubtfull, faint macular erythema only; weak positive reaction, erythema, infiltration papules; strong positive reaction, erythema, infiltration, papular, vesicles; erythema positive reaction, intense erythema, infiltration and coalescing vesicles; negative reaction; irritant reaction; not tested

    72 hours

Study Arms (2)

Gold microparticles

EXPERIMENTAL

Metallic gold microparticles, 20-micron diameter, 1 % w/v in petrolatum

Other: Gold microparticles

Gold thiosulphate

ACTIVE COMPARATOR

Gold Sodium Thio Sulphate, 1 % w/v in petrolatum

Other: Gold thiosulphate

Interventions

Metallic gold microparticles, 20-micron diameter, 1 % w/v in petrolatum

Also known as: Patch test
Gold microparticles

Gold Sodium Thio Sulphate, 1 % w/v in petrolatum

Also known as: Patch test
Gold thiosulphate

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with chronic dermatitis

You may not qualify if:

  • age \< 18

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hypersensitivity

Interventions

Patch Tests

Condition Hierarchy (Ancestors)

Immune System Diseases

Intervention Hierarchy (Ancestors)

Skin TestsImmunologic TestsClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative TechniquesImmunologic Techniques

Study Officials

  • Sten Rasmussen, PhD

    Department of Clinical Medicine, Aalborg Unviversity

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sten Rasmussen, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor Head of Department of Clinical Medicine

Study Record Dates

First Submitted

November 21, 2021

First Posted

March 17, 2022

Study Start

June 1, 2024

Primary Completion

August 31, 2024

Study Completion

October 30, 2024

Last Updated

January 30, 2024

Record last verified: 2024-01